Injex Pharma's wholly owned subsidiary Injex Pharma GmbH has obtained the Chinese State Food and Drug Administration (SFDA) registration for its Injex30 needle free injection system.
The Germany-based company registered the Injex30 with the help of its exclusive distributor Hangzhou Hema Medical Equipment.
The approval process, which took more than 1.5 years, has required a detailed documentation.
The one of the applications of Injex30 is use of insulin for the people suffering from diabetes.
Hangzhou Hema Medical Equipment is planning to start marketing the Injex30 system.
The SFDA regulates the market access of medical devices in the People's Republic of China.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/injex-pharma-receives-chinese-registration-for-needle-free-injection-system-170413
